News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC
14 Sep 2022
byChristina Lau
Pembrolizumab has demonstrated durable efficacy and a manageable adverse event (AE) profile in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib in a 5-year follow-up of the KEYNOTE-224 study.
14 Sep 2022







